Company Description
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally.
The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives.
In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health.
It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health.
Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
| Country | United States |
| Founded | 1952 |
| IPO Date | Feb 1, 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 14,100 |
| CEO | Ms. Kristin C. Peck |
Contact Details
Address: 10 Sylvan Way Parsippany, New Jersey 07054 United States | |
| Phone | 973-822-7000 |
| Website | zoetis.com |
Stock Details
| Ticker Symbol | ZTS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001555280 |
| CUSIP Number | 98978V103 |
| ISIN Number | US98978V1035 |
| Employer ID | 46-0696167 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kristin C. Peck | Chief Executive Officer and Director |
| Wetteny N. Joseph | Executive Vice President and Chief Financial Officer |
| Wafaa Mamilli | EVice President, Chief Digital and Tech. Officer, Group President for China, Brazil and Preci. Animal Health |
| Heidi C. Chen | Executive Vice President, General Counsel, Corporate Secretary and Business Lead of Human Health Diagnostics |
| Dr. Robert J. Polzer Ph.D. | Executive Vice President and President of Research and Development |
| Roxanne Lagano | Executive Vice President and Chief Human Resources Officer and Global Operations |
| Steven Frank | Vice President of Investor Relations |
| William Price | Vice President and Chief Communications Officer |
| Jeannette Ferran Astorga | Executive Vice President of Corporate Affairs and Communications and Chief Sustainability Officer |
| Nick Ashton | Executive Vice President and President of Global Manufacturing and Supply |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 30, 2024 | SD | Form - SD |
| May 24, 2024 | 8-K | Current Report |
| May 23, 2024 | 8-K | Current Report |
| May 22, 2024 | 8-K | Current Report |
| May 8, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 7, 2024 | 144 | Filing |
| May 6, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 2, 2024 | 10-Q | Quarterly Report |
| May 2, 2024 | 8-K | Current Report |
| Apr 18, 2024 | 144 | Filing |